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Background: Insulin resistance, as a key mediator of metabolic syndrome, is thought to be associated with
pathogenesis of calcific aortic valve disease and altered left ventricular (LV) function and structure. However, in
patients with aortic valve sclerosis (AVS), the association between insulin resistance and subclinical impairment of
LV function is not fully elucidated.
Methods: We studied 57 patients (mean age 70 ± 8 years, 22 women) with asymptomatic AVS but normal LV
ejection fraction in echocardiography. LV longitudinal and circumferential strain and strain rate was analyzed using
two-dimensional speckle tracking echocardiography. Patients with uncontrolled hypertension and diabetes mellitus,
chronic kidney disease, and concomitant coronary artery disease were excluded. They were divided into the
insulin-resistant group (AVS+IR; N = 28) and no insulin-resistant group (AVS−IR; N = 29) according to the median
value of homeostatic model assessment index. Computed tomography scans were also performed to measure
the aortic valve calcium score and the visceral adipose tissue (VAT) area. In addition, age- and sex- adjusted 28
control subjects were recruited for the comparison.
Results: There were no significant differences in LV ejection fraction or mass index among the groups. The AVS+IR
group had a higher aortic valve calcium score (median 94 versus 21, P = 0.022) and a larger VAT area (113 ± 42 cm2
versus 77 ± 38 cm2, P = 0.001) than the AVS−IR group. Notably, LV global longitudinal strain, strain rate (SR), and
early diastolic SR were significantly lower in the AVS+IR group than in the AVS−IR group and in control subjects
(strain: −16.2 ± 1.6% versus −17.2 ± 1.2% and −18.9 ± 0.8%; SR: −1.18 ± 0.26 s−1 versus −1.32 ± 0.21 s−1 and −1.52 ±
0.08 s−1; early diastolic SR: −1.09 ± 0.23 s−1 versus −1.23 ± 0.18 s−1 and −1.35 ± 0.12 s−1; P < 0.05 for all comparison),
whereas circumferential function were not significantly different. Multiple linear regression analyses revealed
insulin resistance as an independent determinant of LV longitudinal strain (P = 0.017), SR (P = 0.047), and early
diastolic SR (P = 0.049) regardless of LV mass index or VAT area.
Conclusions: Insulin resistance is a powerful independent predictor of subclinical LV dysfunction regardless of
concomitant visceral obesity and LV hypertrophy. Thus, it may be a novel therapeutic target to prevent
subsequent heart failure in patients with AVS.
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Aortic valve sclerosis (AVS) is a common echocardio-
graphic finding in the elderly and is defined as calcified
and thickened aortic leaflets without restriction of leaflet
motion [1]. This is in contrast to aortic valve stenosis, in
which the motion of calcified and thickened leaflets is
restricted. AVS is associated with increased cardiovascu-
lar risk [2] and subclinical atherosclerosis [3] leading to
cardiovascular mortality and morbidity [4]. Interestingly,
AVS increases the risk of developing congestive heart
failure even in the absence of hemodynamically significant
obstruction of left ventricular (LV) outflow [1].
The constellation of conditions comprising a dysmeta-
bolic state, such as insulin resistance (IR), excess visceral
adiposity, dyslipidemia, and proinflammation, is often
referred to as metabolic syndrome [5]. In the previous
clinical trial, in addition to compensatory LV hyper-
trophy caused by pressure overload, IR was a powerful
independent predictor of progression of LV hypertrophy
in patients with calcific aortic valve stenosis [6]. In
addition, several studies indicate that both IR and vis-
ceral obesity are associated with not only the incidence
of AVS [7] but also impaired LV systolic and diastolic
function even after accounting for comorbidities such
as coronary artery disease [8,9]. However, the association
between IR and an impairment of LV function in AVS
remains unclear.
To date, LV ejection fraction is the most commonly
used method to assess myocardial function. However, it
is not a sensitive measure of systolic dysfunction in
aortic stenosis [10]. Compared to LV ejection fraction,
myocardial strain and strain rate (SR) analyses are
more sensitive indices of LV function and have been
shown to be impaired in aortic stenosis despite normal
LV ejection fraction [10,11]. Myocardial strain and SR
can be measured accurately using two-dimensional
speckle-tracking echocardiography.
These findings evoke the hypotheses that: 1) in patients
with AVS, metabolic disorder associated with IR predis-
poses a patient to early impairment of LV function; and 2)
IR is an essential mediator of this association regardless
of concomitant visceral obesity and LV hypertrophy.
Thus, we tested the hypothesis that IR is associated with
subclinical abnormalities of LV function assessed by




The study was a part of prospective observational studies
investigating disease progression and chronic complica-
tion in patients with AVS. Patients were enrolled if AVS
were detected by Doppler echocardiography and were re-
ferred to cardiac computed tomography (CT) examinationat the Hiroshima University Hospital. In the present study,
asymptomatic AVS patients with preserved LV ejection
fraction ≥50% who were recruited were studied to clar-
ify the associations between subclinical LV dysfunction
and IR.
AVS was defined as focal or diffuse calcification and
thickening of the aortic leaflets without restriction of
leaflet motion on echocardiography using the criteria of
Otto et al. [1]. Exclusion criteria for all AVS patients were
(i) obstructive coronary artery disease, as assessed by car-
diac CT angiography; (ii) prior cardiovascular disease; (iii)
known or newly diagnosed diabetes mellitus with glycated
hemoglobin (HbA1c) ≥8.5%, diabetes-related complica-
tions such as proliferative retinopathy and microalbumi-
nuria, or treatment with hypoglycemic agents or insulin;
(iv) glomerular filtration rate <60 mL/min/1.73 m2, as
estimated by the four-variable Modification of Diet in
Renal Disease study equation [12]; (v) resting blood
pressure ≥140/90 mm Hg with or without antihyperten-
sive agents; and (vi) inadequate image quality for speckle
tracking analysis.
All patients gave informed consent before participa-
tion, and the Ethics Committee of Hiroshima University
Hospital approved the study protocol. One hundred pa-
tients were prospectively enrolled from our institution,
of whom 57 met criteria for inclusion in this study. In
addition, a total of 28 age- and sex-matched patients
with atypical chest pain with normal echocardiographic
findings were recruited as control subjects to compare
clinical characteristics and echocardiographic parameters
with the AVS group. None of control subjects had history
of diabetes mellitus, smoking, or hypertension.
Clinical and laboratory data
All patients provided detailed demographic, medical his-
tory, and medication information at enrollment. Height
and body weight were measured to calculate body mass
index (kg/m2). Waist circumference at the umbilicus was
measured to the nearest 0.1 cm. Metabolic syndrome
was diagnosed using modified Adult Treatment Panel III
criteria [13]. The number of metabolic-syndrome com-
ponents (large waist circumference, elevated triglycer-
ides, low high-density lipoprotein cholesterol, elevated
blood pressure, and impaired fasting glucose) was also
assessed. Overnight fasting blood samples were collected
before CT examinations, and serum levels of total choles-
terol, low-density lipoprotein cholesterol, high-density
lipoprotein cholesterol, triglyceride, and high-sensitivity
C-reactive protein and HbA1c levels were measured in
the hospital laboratory. In addition, blood samples were
immediately stored at −80°C after centrifugation. Plasma
total adiponectin, high-molecular-weight adiponectin, and
leptin levels were measured using ELISA with commer-
cially available kits.
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index was calculated using plasma levels of fasting glucose
and insulin in the following formula: insulin (μIU/mL) ×
(glucose [mmol/L]/22.5) [14], and a HOMA index >1.8
was defined as IR.
Doppler echocardiography
An iE33 ultrasound system equipped with an S3 transducer
(Philips Medical Systems, Andover, MA) was used. Mea-
surements were performed with an experienced sonogra-
pher blinded to patients’ clinical data. Peak transaortic
velocity and mean transaortic pressure gradient were mea-
sured using continuous-wave Doppler echocardiography.
Standard LV volume and mass and left atrial volume were
measured according to current recommendations [15]. LV
end-diastolic volume and end-systolic volume were
measured using Simpson’s biplane method to calculate
LV ejection fraction. LV sphericity index was calculated
as the ratio of short to long axis on end-systolic apical
four-chamber view. LV hypertrophy was determined
using LV mass/height2.7 (cutoffs: 47 g/m2.7 in women,
49 g/m2.7 in men) [6]. Mitral inflow and pulmonary ven-
ous velocities were recorded using pulsed-wave Doppler
echocardiography in the apical four-chamber view. Trans-
mitral early (E) and late (A) diastolic velocities and decel-
eration time were measured at the leaflet tips. Pulmonary
venous systolic (S) and diastolic (D) velocities were re-
corded with the sample volume placed at the orifice of the
right superior pulmonary vein in the left atrium. The ratio
of E wave to early diastolic mitral annular velocity (E/e’)
was determined using color-coded tissue Doppler imaging
with the sample volume positioned in the septal mitral
annulus.
Speckle-tracking analysis
For speckle-tracking analysis, standard grayscale two-
dimensional images were acquired in the apical two- and
four-chamber views as well as the parasternal short-axis
views at the level of the papillary muscles. The LV endo-
cardial border was manually traced at end systole and the
region of interest was adjusted to include the entire myo-
cardium. The software then automatically tracked and
determined the two orthogonal LV functions. For each
patient, a composite value for longitudinal strain and
SR was derived from the mean value of both apical
two- and four-chamber views (a total of twelve segments
automatically generated by the software), and the repre-
sentative circumferential strain and SRs of each patient
comprised the mean value of six LV mid-wall short-axis
segments (Figure 1) [16].
Computed tomography
Cardiac CT examinations were performed using a
64-multidetector scanner (LightSpeed VCT, GE Healthcare).Areas of abdominal fat were simultaneously measured from
an image at the level of the umbilicus using commercially
available software (Virtual Place, AZE Inc., Tokyo, Japan).
Subcutaneous adipose tissue (SAT) was defined as the
extraperitoneal fat between the skin and muscles, with
attenuation ranging from −150 to −50 Hounsfield units.
The intraperitoneal portion with the same density as the
SAT layer was defined as visceral adipose tissue (VAT)
[17]. VAT and SAT areas were determined by automated
planimetry. In addition, similar to previous studies, aortic
valve calcium score was calculated from noncontrast axial
images using the Agatston method [3,4].
Statistical analysis
Continuous data with normal distribution are expressed
as mean ± SD and those with skewed distribution as
median (interquartile range). Categorical variables are
presented as number (percentage). The Kruskal-Wallis
test or 1-way ANOVA was used for group comparisons
of continuous variables, and post-hoc testing was per-
formed using the Tukey’s test or the Steel-Dwass method
for variables with and without normal distribution, re-
spectively. Group comparisons of binary variables were
performed using Fisher exact or χ2 test. The Student t test
or Mann-Whitney U test was used to compare CT param-
eters between the AVS groups (AVS+IR versus AVS−IR).
Pearson’s correlation coefficient was calculated to evalu-
ate the associations among HOMA index, adiposity
measures, LV mass, and strain and SR. Multivariate lin-
ear regression analysis was used to identify independent
determinants of LV global strain, systolic SR, and early
diastolic SR. A tolerance of >0.5 was set to avoid multi-
collinearity between the univariate predictors. A prob-
ability value of P < 0.05 was considered significant. All
statistical analysis was performed using SPSS 21.0 (SPSS
Inc, Chicago, IL).
Results
Baseline characteristics in AVS patients with high and low
HOMA indices and control group
The AVS population comprised 35 men and 22 women
with a mean age of 70 ± 8 years. Mean body mass index
was 23 ± 3 kg/m2. Mean systolic blood pressure, diastolic
blood pressure, and heart rate were 124 ± 14 mm Hg,
76 ± 7 mm Hg, and 65 ± 10 beats/min, respectively. Four
patients medicated using β blockers. LV hypertrophy
was found in 6 patients (10.5%).
Table 1 shows baseline clinical characteristics among
the AVS+IR (HOMA index >1.8), AVS−IR (≤1.8), and
the control groups. No significant differences were found
in age and gender. The AVS+IR group had significantly
greater mean body mass index, waist circumference, and
number of metabolic syndrome components; higher





Figure 1 Example of an analysis using speckle-tracking echocardiography. Longitudinal and circumferential strain (left panels) and SR
(right panels) curves are shown. Mean values of peak systolic strain (solid arrow), systolic SR (broken arrow), and early diastolic SR (arrowhead)
are indicated.
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weight adiponectin compared with the AVS−IR group
and control group.
Table 2 summarizes echocardiographic and CT parame-
ters in patients with AVS and control group. The AVS+IR
group had significantly greater computed tomography-
derived adiposity measures (VAT and SAT areas) compared
with the AVS−IR group. No significant differences were
found in LV and left atrial volumes, LV ejection fraction
and mass index, and Doppler indices between two AVS
groups. No significant difference was also found in echocar-
diographic data regarding hemodynamic function of the
aortic valve between two AVS groups, whereas the AVS+IR
group had larger amount of aortic valve calcium compared
with the AVS−IR group. Interestingly, the AVS+IR group
had a higher LV sphericity index compared with the AVS
−IR group and control group.Results of speckle-tracking echocardiography
The mean frame rates for two-dimensional speckle-
tracking analysis in the apical and short-axis views were
81 ± 13 frames/s and 78 ± 12 frames/s, respectively. The
AVS+IR group had significantly reduced LV global longi-
tudinal systolic and diastolic function compared with
other groups (Table 2, Figure 2). Figure 3 depicts the re-
gional longitudinal function in the AVS+IR, the AVS−IR,
and control group. Regional longitudinal strain at the base
(−15.8 ± 1.1% versus −16.5 ± 1.0%, P = 0.035 with posthoc analysis), mid LV (−16.2 ± 1.6% versus −17.2 ± 1.2%,
P = 0.023 with post hoc analysis), and apex (−16.5 ± 2.5%
versus −18.0 ± 1.7%, P = 0.007 with post hoc analysis) was
significantly reduced in the AVS+IR group compared with
the AVS−IR group. In addition, the magnitude of the de-
crease in each segmental strain value in the AVS+IR group
was clearly observed in order of apex, mid LV, and base
(P < 0.001 by ANOVA; apex versus base, P = 0.002 with
post hoc analysis; apex versus mid LV, P = 0.11 with post
hoc analysis). Circumferential strain and SR, however,
were preserved in all groups and did not differ signifi-
cantly (Table 2, Figure 2).Correlation between IR and LV function in patients
with AVS
Table 3 lists age- and sex-adjusted Pearson’s correlations
among HOMA index, adiposity measures, and LV pa-
rameters in patients with AVS. HOMA index and VAT
area had significant negative correlations to LV longi-
tudinal systolic and diastolic function, with correlations
ranging from 0.386 to 0.490 (strain), 0.367 to 0.392 (SR),
and −0.377 to −0.408 (early diastolic SR). LV mass index
was weakly correlated with longitudinal diastolic SR
(R = −0.292, P = 0.027), but not with longitudinal strain
and SR. In addition, VAT area was positively correlated
with HOMA index (R = 0.452, P < 0.001) and LV mass
index (R = 0.350, P = 0.008). None of the LV parameters
was related to SAT area.
Table 1 Baseline clinical characteristics
Variable
AVS+IR group AVS–IR group Control group
P Value§
(n = 28) (n = 29) (n = 28)
Age, y 70 ± 7 71 ± 8 70 ± 9 0.93
Female, n (%) 13 (46) 9 (31) 9 (32) 0.41
Body mass index, kg/m2 25 ± 3*† 22 ± 2 23 ± 3 0.004
Waist circumference, cm 91 ± 8*† 84 ± 7 84 ± 10 0.003
Systolic blood pressure, mm Hg 126 ± 13 122 ± 15 123 ± 18 0.65
Diastolic blood pressure, mm Hg 77 ± 7 75 ± 7 77 ± 14 0.39
Heart rate, beats/min 66 ± 10 65 ± 10 63 ± 6 0.49
Metabolic syndrome, n (%) 7 (25)* 3 (10) 1 (4) 0.042
Number of metabolic syndrome components 1.9 ± 0.9*† 1.3 ± 0.8 0.9 ± 0.9 0.001
Estimated glomerular filtration rate, mL/min 69 ± 17 68 ± 13 75 ± 15 0.19
Fasting glucose, mmol/L 6.5 ± 1.8*† 5.7 ± 0.8 5.3 ± 0.5 0.001
Fasting insulin, μIU/mL 8.9 (7.5–10.7)*† 4.4 (3.5–5.3) 3.9 (2.9–5.2) < 0.001
Total cholesterol, mg/dL 198 ± 33 206 ± 31 197 ± 38 0.52
Low-density lipoprotein cholesterol, mg/dL 117 ± 25 121 ± 28 112 ± 30 0.48
High-density lipoprotein cholesterol, mg/dL 60 ± 13 71 ± 15 66 ± 27 0.11
Triglycerides, mg/dL 113 (89–142) 95 (74–137) 109 (84–179) 0.32
High-sensitivity C-reactive protein, mg/L 1.8 ± 5.2 1.4 ± 2.2 1.0 ± 1.6 0.66
Glycated hemoglobin,% 6.2 ± 1.0* 5.8 ± 0.5 5.5 ± 0.4 0.003
Total adiponectin, μg/mL 8.2 (6.4–12.6)*† 14.7 (8.3–19.0) 14.4 (12.2–17.8) 0.001
High-molecular-weight adiponectin, μg/mL 6.1(4.0–12.7)*† 11.9(4.8–16.1) 11.5 (8.6–14.8) 0.002
Leptin, ng/mL 6.0 (2.8–9.7)*† 3.7 (1.9–4.5) 2.8 (1.7–3.9) < 0.001
Renin angiotensin system inhibitors, n (%) 10 (36) 9 (31) … 0.71‡
β Blockers, n (%) 2 (7) 2 (7) … 0.92‡
Notes: Values are mean ± SD, number (percentage), or median (interquartile range). *P (with post hoc analysis) <0.05 versus control group. †P (with post hoc
analysis) <0.05 versus the AVS−IR group. ‡P values are for χ2 test, Student t test, or Mann–Whitney U test for the AVS+IR versus the AVS−IR group. §P values are
for 1-way ANOVA for all groups unless specified.
Abbreviations: AVS aortic valve sclerosis; IR insulin resistance.
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The results of multiple linear regression analyses in patients
with AVS to investigate the independent determinants
of longitudinal strain, SR, and diastolic SR are presented
in Table 4. For all linear regression models, a HOMA
index of >1.8 was an independent determinant of longi-
tudinal strain (multiple R 0.601, P = 0.017), longitudinal
SR (multiple R 0.561, P = 0.047), and longitudinal diastolic
SR (multiple R 0.555, P = 0.049). VAT area was also closely
associated with longitudinal systolic and diastolic function
in the univariate analyses (P < 0.05 for all), but the value of
VAT area diminished with further adjustment for HOMA
index (Table 4).Reproducibility
Longitudinal strain, SR, and diastolic SR had per-
missible intraobserver and interobserver variability
(strain, 0.4 ± 0.2% and 0.5 ± 0.3%; SR, 0.08 ± 0.04 1/sand 0.09 ± 0.06 1/s; diastolic SR, 0.09 ± 0.06 1/s and
0.14 ± 0.08 1/s, respectively).Discussion
The present study demonstrates that LV longitudinal
function has been already impaired in a group of pa-
tients with AVS and that IR is a powerful independent
predictor of subclinical abnormalities of LV longitudinal
function in patients with AVS. This negative contribution
of IR to LV function remained significant even after ad-
justment for demographic variables, LV mass index, and
visceral adiposity on multiple linear regression analysis.Impairment of global LV function in AVS
This study demonstrates subclinical abnormalities of
global LV systolic and diastolic function, as reflected by
reduced LV longitudinal, not circumferential, strain and
SRs, which are more sensitive indices of LV contractility
Table 2 Echocardiographic and CT parameters
Variable
AVS+IR group AVS−IR group Control group
P Value§
(n = 28) (n = 29) (n = 28)
Peak transaortic velocity, m/s 1.6 ± 0.4* 1.6 ± 0.3* 1.2 ± 0.2 < 0.001
Mean transaortic pressure gradient, mm Hg 6 ± 2* 5 ± 2* 3 ± 1 < 0.001
LV mass index, g/m2.7 39 ± 6 36 ± 9 37 ± 5 0.20
LV hypertrophy, n (%) 3 (11) 3 (10) 0 (0) 0.19
LV end-diastolic volume, mL 85 ± 27 81 ± 20 83 ± 12 0.79
LV end-systolic volume, mL 27 ± 14 26 ± 13 26 ± 6 0.94
LV ejection fraction,% 70 ± 11 69 ± 8 68 ± 5 0.84
LV sphericity index 0.46 ± 0.04*† 0.43 ± 0.05* 0.40 ± 0.03 < 0.001
Left atrial volume index, mL/m2 29 ± 7* 29 ± 9* 25 ± 3 0.011
Transmitral E/A ratio 0.8 ± 0.4 0.8 ± 0.2 0.8 ± 0.1 0.59
Transmitral deceleration time, ms 233 ± 55 244 ± 50 224 ± 32 0.27
Pulmonary S/D ratio 1.6 ± 0.5 1.5 ± 0.3 1.5 ± 0.2 0.25
E/e’ ratio 12.5 ± 3.5* 11.1 ± 3.4* 8.5 ± 1.3 < 0.001
Longitudinal strain,% −16.2 ± 1.6*† −17.2 ± 1.2* −18.9 ± 0.8 < 0.001
Longitudinal SR, s−1 −1.18 ± 0.26*† −1.32 ± 0.21* −1.52 ± 0.08 < 0.001
Longitudinal diastolic SR, s−1 1.09 ± 0.23*† 1.23 ± 0.18* 1.35 ± 0.12 < 0.001
Circumferential strain,% −22.9 ± 0.8 −23.2 ± 0.6 −23.1 ± 0.7 0.31
Circumferential SR, s−1 −1.39 ± 0.04 −1.39 ± 0.04 −1.40 ± 0.05 0.91
Circumferential diastolic SR, s−1 1.90 ± 0.11 1.89 ± 0.08 1.88 ± 0.09 0.68
VAT area, cm2 113 ± 42 77 ± 38 … 0.001‡
SAT area, cm2 163 ± 74 127 ± 47 … 0.037‡
VAT/total fat ratio,% 42 ± 15 37 ± 13 … 0.18‡
Aortic valve calcium score 94 (11–197) 21 (6–54) … 0.022‡
Notes: Values are mean ± SD, number (percentage), or median (interquartile range). *P (with post hoc analysis) <0.05 versus control group. †P (with post hoc
analysis) <0.05 versus the AVS−IR group. ‡P values are for χ2 test, Student t test, or Mann–Whitney U test for the AVS+IR versus the AVS−IR group. §P values are
for 1-way ANOVA for all groups unless specified.
Abbreviations: A late filling velocity; CT computed tomography; E early filling velocity; e’: early diastolic mitral annular velocity; HOMA homeostatic model
assessment; LV left ventricular; SAT subcutaneous adipose tissue; S/D systolic/diastolic; SR strain rate; VAT visceral adipose tissue.
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cross-sectional sub-studies of the ASTRONOMER trial
have pointed out the impact of metabolic syndrome
not only on progression of aortic stenosis, but also on
progression of LV hypertrophy and reduced myocardial
velocities in patients with mild and moderate aortic
stenosis [7,18]. Furthermore, the metabolic abnormal-
ities linked to IR, metabolic syndrome, and diabetes
mellitus have an additive adverse effect on the preva-
lence and progression of LV hypertrophy and reduced
global LV longitudinal function in patients with aortic
stenosis beyond known factors of pressure overload
[6,11]. The association between valve disease and myo-
cardial abnormality in those studies [6,18], however,
are rarely investigated in patients with AVS, which is
considered as an early, asymptomatic stage of calcific
aortic valve disease. Ng et al. [19] reported on impair-
ment of global longitudinal strain and SRs in patientswith type 2 diabetes mellitus, suggesting that the in-
jured myocardial fibers are located predominantly in
the epicardium/endocardium. However, these results
could have been influenced by potential confounding
comorbidities, such as unregulated hypertension, chronic
kidney disease, coronary artery disease, and concomitant
LV hypertrophy [20], because AVS has been associated
with cardiovascular risk factors and coronary atheroscler-
osis [2,3]. In this study, we therefore excluded patients
with several of these comorbidities, including coronary
artery disease (exclusion based on coronary computed
tomography angiography).
In the Cardiovascular Health Study [1], AVS has in-
creased the risk of developing congestive heart failure
even in the absence of hemodynamically significant
obstruction of LV outflow. However, the mechanism by
which AVS influences LV function has not been suffi-
























































































AVS+IR Group (HOMA index > 1.80)
Control Group
P=0.31 (ANOVA) P=0.91 (ANOVA) P=0.68 (ANOVA)
P<0.001(ANOVA) P<0.001 (ANOVA)
P=0.027 (post hoc) P=0.019 (post hoc)
Figure 2 Global longitudinal and circumferential function in the AVS+IR (pink bar), the AVS−IR (green bar), and control group (blue
bar). The AVS+IR group had significantly lower median levels of longitudinal strain, longitudinal SR, and longitudinal diastolic SR than the AVS−IR
group and control group. Circumferential strain and SRs showed no statistically significant differences. Boxes indicate 25th and 75th percentiles,
and lines indicate 5th and 95th percentiles, for the data.
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failure is partly due to adverse effects of IR in patients
with AVS. In addition, these results may have important
clinical implications with regard to life style modification
in this setting.IR and AVS progression
Our results also suggest that IR is an important medi-
ator of the association between AVS and subclinical LV
dysfunction. IR, a central feature of metabolic syn-
drome and diabetes mellitus, has been a causative or
contributing factor in the pathogenesis of AVS. Several
prospective studies have shown that metabolic syn-
drome is associated with increased prevalence and
incidence of AVS [21]. Also in the present study, we
demonstrated that the AVS+IR group had a higher aor-
tic valve calcium score along with a larger VAT area.
Moreover, recent studies have implicated the renin-
angiotensin system, which is upregulated in metabolic
syndrome [22], in aortic valve disease pathogenesis
[23]. Currently, no medical interventions are capable
of delaying or halting AVS progression. Whether the
treatment of IR targeted to patients with AVS leads toboth preventing subclinical LV dysfunction and slow-
ing the progression of calcific aortic valve disease is
need to be clarified in future prospective studies.Pathogenesis of adverse effects of IR on LV function
and remodeling
Previous studies have indicated the close relationship
between impaired LV longitudinal function and dysme-
tabolic state, such as diabetes mellitus [24], normal-
weight obesity (visceral obesity) [25], and nonalcoholic
steatohepatitis [26]. Our study provides novel informa-
tion suggesting the role of IR on an early impairment
of the longitudinal function, independently of concomi-
tant visceral obesity and LV hypertrophy. These data may
fit with recent evidence showing a strong link between
IR and reduced LV contractile reserve [8], leading to
non-ischemic heart failure [27]. The concept of a spe-
cific insulin-resistant cardiomyopathy is now emerging
[28]. Diffuse interstitial fibrosis throughout the myocar-
dium of diabetic patients suggests widespread cardiomyo-
cyte damage and the influence of cytokine activity.
Domenighetti et al. [29] demonstrated that cardiac IR














P=0.023 (post hoc) P=0.007 (post hoc)
P<0.001 (ANOVA) P<0.001 (ANOVA) P<0.001 (ANOVA)
AVS+IR Group (HOMA index > 1.80)
ControlGroup
Figure 3 Regional longitudinal strain in the AVS+IR (pink bar),
the AVS−IR (green bar), and control group (blue bar). Longitudinal
strain in the AVS+IR group, the AVS−IR group, and control group along
the LV wall base, mid, and apex is shown. The decrease in longitudinal
strain is more pronounced at the mid-apical than basal portions of the
LV wall in the AVS+IR group.
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take. A shift away from glycolysis towards fatty acid
oxidation for ATP supply is associated with myocardial
oxidative stress and induces profound alterations in
cardiomyocyte Ca2+ homeostasis [29]. Recent studies
have shown that LV hypertrophy and interstitial fibrosis
can also be triggered by activation of several insulin-
related signaling pathways, altered adipokine levels
(including leptin and adiponectin), or the activity of
peroxisome proliferator-activated receptors, all indicating
that metabolic disorders may play a role in the patho-
physiology of LV dysfunction [30]. Also in this study,Table 3 Age- and sex-adjusted Pearson’s correlations betwee
patients with AVS
HOMA index VAT area SAT area LV mass in
HOMA index –
VAT area 0.452‡ –
SAT area NS NS –
LV mass index NS 0.350† NS –
Longitudinal strain 0.386† 0.490‡ NS NS
Longitudinal SR 0.367† 0.392† NS NS
Longitudinal diastolic SR −0.408† −0.377† NS −0.292*
Notes: *P < 0.05; †P < 0.01; ‡P < 0.001.
Abbreviation: NS indicates no siginificant.higher plasma level of leptin and lower levels of total
and high-molecular-weight adiponectin were shown in
the AVS+IR group. Mellor et al. [31] suggested that
significant cardiomyocyte loss in the insulin-resistant
heart is driven by a non-apoptotic type of programmed
cell death: autophagy. The insulin resistant myocardium
exhibits various pro-autophagic characteristics, including
suppression of the PI3K(I)-Akt signaling pathway and
metabolic dysregulation, making the affected heart prone
to autophagic demise [31].Regional LV function and spherical alteration in AVS
The present study also provides the interesting finding
that LV longitudinal strain alteration shows mid-apical
predominance. Possible mechanisms include the distri-
bution of insulin receptor [32], the change in regional
stress–strain relationship due to apical thin wall, and LV
remodeling [33]. In this study, the shape of the LV was
more spherical in patients with a high HOMA index
than in those with a low HOMA index. However, whether
LV spherical alteration in AVS translates to regional longi-
tudinal dysfunction remains to be addressed in larger-
scale studies.Limitations
First, although our data support the notion that IR is an
important factor in the pathogenesis of LV dysfunction
in patients with AVS, causality cannot be fully estab-
lished because this is a cross-sectional study. Further-
more, larger prospective and larger-population studies
are needed to clarify whether IR per se could be held
responsible to the subclinical LV dysfunction inde-
pendently of the metabolic syndrome with all its risk
factors. However, we could reach the statistical signifi-
cance in the multiple linear regression models including
visceral obesity (i.e., key component of the metabolic
syndrome). Second, in this study, the serum level of
high-sensitivity C-reactive protein was not associatedn HOMA index, adiposity measures, and LV parameters in




Table 4 Independent determinants of LV longitudinal systolic and diastolic function in patients with AVS
Variable t
Longitudinal strain Longitudinal SR Longitudinal diastolic SR
β (S.E.) P Value β (S.E.) P Value β (S.E.) P Value
Age 0.815 −0.230 NS −0.196 NS 0.215 NS
(Per 10 y) (0.253) (0.041) (0.037)
Female sex 0.753 −0.039 NS −0.204 NS 0.074 NS
(Yes) (0.410) (0.067) (0.060)
Body mass index 0.535 −0.370 0.022 −0.302 0.067 0.354 0.034
(Per 1 kg/m2) (0.084) (0.014) (0.012)
Systolic blood pressure 0.835 0.295 0.022 0.325 0.015 −0.263 0.048
(Per 10 mm Hg) (0.136) (0.022) (0.020)
LV mass index 0.865 −0.066 NS −0.017 NS −0.146 NS
(Per 10 g/m2.7) (0.241) (0.039) (0.035)
VAT area 0.541 0.349 0.029 0.157 NS −0.239 NS
(Per 10 cm2) (0.054) (0.009) (0.008)
HOMA index 0.752 0.327 0.017 0.279 0.047 −0.277 0.049
(>1.8) (0.399) (0.065) (0.058)
Abbreviations: NS no significant; S.E. standard error; t tolerance.
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http://www.cardiab.com/content/13/1/86with IR and impairment of LV function. However, a
previous article [34] demonstrates that other inflam-
matory markers, such as tumor necrosis factor-α and
IL-6, are the mediators of the hyperinsulinemic state
specifically related to excess adiposity. Third, we de-
fined IR in terms of the median HOMA index value of
1.8. In general, a HOMA index < 2 is believed to be
normal in Caucasian. Because the insulin secretion
capacity in Japanese is lower than that in Caucasian
[35], the lower threshold of HOMA index would be
reasonable. Thus, larger observational studies includ-
ing other ethnic group will be required to confirm our
findings.
Finally, current two-dimensional speckle-tracking ana-
lysis is affected by cardiac motion; namely, through-plane
motion. In particular, the values of radial strain and
SR are likely to be susceptible to this effect. Thus, we
omitted data in the radial direction. However, the
easy availability and non-invasiveness of two-dimensional
speckle-tracking echocardiography may allow assess-
ment of patients with AVS and concomitant insulin-
resistant cardiomyopathy and observation of disease
progression.Conclusions
IR is an independent determinant of subclinical abnor-
malities of LV longitudinal function in patients with
AVS, as assessed by two-dimensional speckle-tracking
echocardiography, even after adjustment for concomi-
tant visceral obesity and LV hypertrophy. Our results
may have important clinical implications with regardto life style modification and raise the possibility that
optimizing IR proves an effective approach to preventing
subclinical LV dysfunction in this setting.
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